Accessing Kanexthal
Our first certified hospital approved for Kanexthal’s commercial access is Guangzhou First People's Hospital, Nansha Branch, in Guangzhou China. This specialized center is equipped with state-of-the-art hematology and gene therapy units in addition to being managed by experienced teams, ensuring every step of the treatment meets international quality and safety standards. Kanglin is working closely with qualified hospitals for future
expansion of Kanexthal’s commercial access
Guangzhou First People's Hospital (Nansha)
The treatment process requires a series of coordinated steps that must be done under strict medical supervision at our GMP-compliant facility in Guangzhou First People's Hospital, Nansha Branch.
Guangzhou First People's Hospital is a world-class facility with an experienced medical team dedicated to providing the best care for patients undergoing gene therapy.
Because Kanexthal is an advanced, highly regulated gene therapy, it can only be administered in approved facilities that meet strict manufacturing and clinical quality requirements.
The Nansha site allows our team to ensure precision, safety, and full regulatory oversight, providing every patient the best chance at a successful outcome.
While travel may seem challenging, it allows patients to receive personalized care directly from the Kanexthal development team, who bring years of experience in gene therapy and hematological disorders.
By traveling to Guangzhou, patients gain access to cutting-edge facilities and specialized expertise not yet widely available in other regions.
Support beings here
A dedicated patient access team can help you navigate next steps: from documents to logistics and assistance pathways.
Explain required documents (genotype reports, transfusion history, lab tests, imaging) and how to submit.
Travel & logistics
Share practical guidance for travel planning and expected visit windows, prioritizing patience convenience.
Coordination & translation
Coordinate care steps and provide translation support for international patients.
Assistance pathways
If some tests are not available in your country, we will work alongside you to share possible providers or channels based on location accessibillity.
Donation campaign
Eligible transfusion-dependent β-thalassemia (TDT) patients may receive up to ~60% cost coverage through a 1:1.5 donation-matching program, with enrollment limited to three patients per country/region.